Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB

Lymphoma Clinical Trial

Official title:

A Phase 1 Study of [ 14 C]-Ixazomib to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01953783
• Other study ID #: C16016
• Status: Completed
• Phase: Phase 1
• Start date: March 19, 2014
• Est. completion date: February 9, 2016

Study information

• Verified date: August 2020
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 1, 2-part, open-label study in 4 to 6 pharmacokinetic-evaluable participants with advanced solid tumors or lymphoma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. completion date: February 9, 2016
• Est. primary completion date: December 17, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Each participant must meet all of the following inclusion criteria to be enrolled in the study:

• 18 years or older

• Histologic or cytologic diagnosis of advanced or metastatic solid tumor or lymphoma for which no standard, curative, or life-prolonging therapies exist or are effective

• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2

• Female participants who are postmenopausal for at least 1 year OR are surgically sterile OR if of childbearing potential, agree to practice 2 effective methods of contraception at the same time during the entire study through 90 days after the last dose of study drug OR agree to practice true abstinence

• Male participants who agree to practice effective barrier contraception during the entire study and through 90 days after the last dose of study drug OR agree to practice true abstinence

• Voluntary written consent

• Suitable venous access for the conduct of blood sampling

• Recovered from the reversible effects of prior anticancer therapy

Exclusion Criteria:

Participants meeting any of the following exclusion criteria are not to be enrolled in the study:

• Female participants who are lactating or breastfeeding or have a positive serum pregnancy test

• Serious medical or psychiatric illness that could interfere with the study

• Treatment with any investigational products or radiotherapy within 21 days before the first dose of study drug

• Peripheral neuropathy greater than (>) Grade 2

• Systemic treatment with strong and moderate inhibitors of CYP1A2, strong and moderate inhibitors of CYP3A, or clinically significant CYP3A inducers or use of Ginkgo biloba or St. John's wort within 14 days before the first dose of study drug

• Symptomatic brain metastasis. Participants with brain metastases: must have stable neurologic status following local therapy (surgery or radiation) for at least 2 weeks after completion of the definitive therapy; and must be without neurologic dysfunction that would confound the evaluation of neurologic and other adverse events (AEs)

• Ongoing treatment with corticosteroids

• Major surgery within the 14 days preceding the first dose of study drug

• Infection requiring systemic intravenous antibiotic therapy or other serious infection within 14 days before the first dose of study drug

• Life-threatening illness unrelated to cancer

• Known hepatitis B surface antigen -positive, or known or suspected active hepatitis C infection or human immunodeficiency virus (HIV) positive

• Diagnosed or treated for another malignancy within 2 years before the first dose, OR previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

• Any cardiovascular condition specified in the study protocol

• Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of IXAZOMIB

• History of urinary and/or fecal incontinence

• Inability to comply with study procedures or visit schedule including the requirement for inpatient confinement

Related Conditions & MeSH terms

• Advanced Solid Tumors
• Lymphoma

Intervention

Drug:
• IXAZOMIB
Part A: Ixazomib 4.1 mg containing approximately 500-nCi [14C]-ixazomib, solution, orally on Day 1 and ixazomib 4 mg, capsule, orally on Days 14 and 21. Part B: Ixazomib 4 mg, capsule, orally, once weekly, on Days 1, 8 and 15 in 28-day cycles until disease progression or unacceptable toxicity.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Millennium Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part A: Cmax: Maximum Observed Plasma Concentration for Ixazomib	Maximum observed plasma concentration (Cmax) is the peak plasma concentration of ixazomib, obtained directly from the plasma concentration-time curve.	Day 1 of Part A pre-dose and at multiple timepoints (up to Day 14) post-dose
Primary	Part A: Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Ixazomib	Time to reach the maximum observed plasma concentration (Cmax), equal to time (hours) to Cmax of ixazomib after administration, obtained directly from the plasma concentration-time curve.	Day 1 of Part A pre-dose and at multiple timepoints (up to Day 14) post-dose
Primary	Part A: AUC(0-312): Area Under the Plasma Concentration-time Curve From Time 0 to 312 Hrs Post-dose for Ixazomib	AUC(0-312) is a measure of the area under the plasma concentration time-curve from time zero to 312 hrs post-dose for ixazomib.	Day 1 of Part A pre-dose and at multiple timepoints (up to 312 hrs) post-dose
Primary	Part A: Cmax: Maximum Observed Plasma Concentration of TRA	Maximum observed plasma concentration (Cmax) of TRA is the peak plasma concentration of TRA, obtained directly from the plasma TRA concentration-time curve.	Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
Primary	Part A: Tmax: Time to Reach the Cmax for TRA	Time to reach the maximum observed plasma concentration (Cmax) for TRA, equal to time (hours) to Cmax for TRA after administration, obtained directly from the plasma TRA concentration-time curve.	Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
Primary	Part A: AUC(0-816): Area Under the Plasma Concentration-time Curve From Time 0 to 816 Hrs Post-dose for TRA	AUC(0-816) is a measure of the area under the plasma concentration time-curve from time zero to 816 hrs post-dose for TRA.	Day 1 of Part A pre-dose and at multiple timepoints (up to 816 hrs) post-dose
Primary	Part A: Cmax: Maximum Observed Whole Blood Concentration of TRA	Maximum observed whole blood concentration (Cmax) of a TRA is the peak whole blood concentration of TRA, obtained directly from the whole blood TRA concentration-time curve.	Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
Primary	Part A: Tmax: Time to Reach the Maximum Observed Whole Blood Concentration (Cmax) for TRA	Time to reach the maximum observed whole blood concentration (Cmax) for TRA, equal to time (hours) to Cmax for TRA after administration, obtained directly from the whole blood TRA concentration-time curve.	Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
Primary	Part A: AUC(0-816): Area Under the Whole Blood Concentration-time Curve From Time 0 to 816 Hrs Post-dose for TRA	AUC(0-816) is a measure of the area under the whole blood concentration time-curve from time zero to 816 hrs post-dose for TRA.	Day 1 of Part A pre-dose and at multiple timepoints (up to 816 hrs) post-dose
Primary	Part A: Cumulative Percentage of Ixazomib Dose Recovered in the Urine	Percentage of the ixazomib dose excreted unchanged in the urine from 0 to 168 hrs post-dose.	Day 1 of Part A from 0 to pre-dose and at multiple timepoints (up to 168 hrs) post-dose
Primary	Part A: Cumulative Percentage of the Total Radioactivity Dose Excreted in Feces	Percentage of the TRA dose excreted in feces from Day 1 to Day 35 of Part A	Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
Primary	Part A: Cumulative Percentage of the Total Radioactivity Dose Excreted in Urine	Percentage of the TRA dose excreted in urine from Day 1 to Day 35 of Part A.	Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
Primary	Part A: Renal Clearance of Ixazomib	Renal clearance is the volume of plasma from which ixazomib is completely removed by the kidney in a given amount of time, calculated as the amount of ixazomib excreted in the urine divided by the area under the plasma ixazomib concentration-time curve.	Day 1 pre-dose and at multiple timepoints (up to Day 14) post-dose
Secondary	Ixazomib and Metabolites as Percent of Total Radioactivity in Plasma	The plasma samples were pooled for participants over 816 hrs post-dose, and data was analysed using the Hamilton method time-proportional pooling, and therefore the data is reported as "percent of total radioactivity in plasma" with measure type as "number" and measure dispersion as "Not applicable, NA".	Day 1 pre-dose and at multiple time points (up to 816 hrs) post-dose
Secondary	Ixazomib and Metabolites as Percent of Total Dose Administered in Urine	The 35-day post-dose data is extrapolated from the average of four participant data from 0-168-hr pooled urine. The data is therefore reported as "percentage of dose" with measure type as "number" and measure dispersion as "NA".	Day 1 pre-dose and at multiple time points (up to Day 35) post-dose
Secondary	Ixazomib and Metabolites as Percent of Total Dose Administered in Feces	The 35-day post-dose data is extrapolated from the average of four participant data from 0-168-hr pooled feces. The data is therefore reported as "percentage of dose" with measure type as "number" and measure dispersion as "NA".	Day 1 pre-dose and at multiple time points (up to Day 35) post-dose
Secondary	Number of Participants Reporting One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)		Baseline up to Cycle 5 Day 45
Secondary	Number of Participants With TEAEs Related to Investigations System Organ Class for Laboratory Values		Baseline up to Cycle 5 Day 45
Secondary	Number of Participants With TEAEs Related to Vital Signs	Vital signs included oral body temperature, heart rate, and blood pressure.	Baseline up to Cycle 5 Day 25